A study of intravenous zanamivir in adults, teenagers and children with influenza
- Conditions
- Hospitalized adult, adolescent and pediatric subjects with influenza infection.MedDRA version: 17.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Registration Number
- EUCTR2009-016035-35-Outside-EU/EEA
- Lead Sponsor
- GlaxoSmithKline Research & Development Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- A
- Sex
- All
- Target Recruitment
- 200
1. Male or female aged = 6 months of age; a female is eligible to enter and participate in the study if she is:
a. of non-childbearing potential (i.e., physiologically incapable of becoming
pregnant, including any female who is post-menopausal); or,
b. of child-bearing potential, has a negative pregnancy test at Baseline, and agrees to one of the following methods for avoidance of pregnancy during the study and until the Post-Treatment +23 Days Follow-up Assessment:
• Abstinence; or,
• Oral contraceptive, either combined or progestogen alone; or,
• Injectable progestogen; or,
• Implants of levonorgestrel; or,
• Estrogenic vaginal ring; or,
• Percutaneous contraceptive patches; or
• Intrauterine device (IUD) or intrauterine system (IUS) showing that the
expected failure rate is less than 1% per year as stated in the IUD or IUS
Product Label; or,
• Has a male partner who is sterilized; or,
• Double barrier method: condom and an occlusive cap (diaphragm or
cervical/vault caps) with a vaginal spermicidal agent
(foam/gel/film/cream/suppository).
2. Subjects who have confirmed influenza as determined by a positive result in a rapid test for influenza A or influenza B, or a laboratory test for influenza including influenza virus antigen test, virus culture or RT-PCR test. Subjects with negative rapid test result suspected of having influenza can be enrolled following confirmatory testing by RT-PCR, antigen test or culture.
3. Hospitalized subjects with symptomatic influenza.
4. Subjects who are able to receive their first dose of study medication within seven days of experiencing influenza-like symptoms.
5. Inclusion Criteria #5 was removed in Protocol Amendment 04.
6. Subjects willing and able to adhere to the procedures stated in the protocol.
7. Subjects/legally acceptable representative (LAR) of minors and unconscious adults willing and able to give written informed consent to participate in the study (or included as permitted by local regulatory authorities, IRB/IECs or local laws).
8. French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
9. UK subjects and subjects in Spain: Subjects should be in a high dependency or intensive care setting at the time of enrolment and either have severe and progressive illness on approved influenza antiviral agents, or are considered unsuitable for treatment with approved influenza antivirals.
10. Subjects who have severe or progressive influenza illness on approved (fully licensed) influenza antiviral agents, or who are considered unsuitable or inappropriate for treatment with approved influenza antivirals, or who in the opinion of the investigator may benefit from IV zanamivir therapy.
Subjects who meet the entry criteria are considered eligible for the study. This includes, but is not limited to subjects who are intubated/ventilated or receiving extracorporealmembrane oxygenation (ECMO), immunocompromised, HIV positive or have renal impairment and subjects who may have received prior licensed anti-influenza medication.
Are the trial subjects under 18? yes
Number of subjects for this age range: 50
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 100
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 35
1.Subjects who, in the opinion of the investigator, are not likely to survive the next 48 hours beyond Baseline.
2.Subjects who require concurrent therapy with another influenza antiviral drug.
3.Subjects who have participated in a study using an investigational influenza antiviral drug within 30 days prior to Baseline.
4.Subjects who are known or suspected to be hypersensitive to any component of the study medication.
5.Subjects who meet the following criteria at Baseline:
ALT > 3xULN and bilirubin > 2xULN or ALT > 5xULN
6.History of cardiac disease or clinically significant arrhythmia (either on ECG or by history) which, in the opinion of the Investigator, will interfere with the safety of the individual subject.
7.QT criteria at baseline as defined: QTcB or QTcF > 500 msec; If subject has bundle branch block then criteria is QTcB or QTcF > 530 msec.
8.Child in care (CiC) as defined below:
A child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
The definition of a CiC can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a CiC does not include a child who is adopted or has an appointed legal guardian.
9. French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days. This criterion may also apply in other countries if required by local regulatory authorities or IRB/IECs.
10. Females who are pregnant (positive urine or serum pregnancy test at Baseline) or are breastfeeding.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method